What IQVIA's Quarter ended Sep 30, 2026 10-Q says: 4 signals
IQVIA filed its latest 10-Q with the SEC on Oct 27, 2026. It discusses bookings decline, international growth and restructuring.
Get IQVIA's live signals in Claude or ChatGPT, or by API
What changed at IQVIA this week? Use Autobound signals for iqvia.com.- Filed
- Oct 27, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 13
Source: Autobound Signal API · 71 signals tracked for IQVIA · updated
10-Q · latest 10
What IQVIA's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
IQVIA reorganized business reporting into two segments effective January 1, 2026
IQVIA updated its operating model and reorganized from three segments into Commercial Solutions and Research & Development Solutions effective January 1, 2026.
IQVIA incurs $150 million in nine-month restructuring charges to streamline global operations
Restructuring costs reached $36 million in Q3 2026 and $150 million for the first nine months of 2026 as part of efforts to streamline operations, eliminate redundant positions, and integrate acquisitions.
Commercial Solutions Achieves Constant Currency Revenue Growth in Americas, Europe, Africa, and APAC
Commercial Solutions revenue grew 6.9% to $1,789 million in Q3 2026, driven by constant currency growth in the Americas, Europe and Africa, and Asia-Pacific regions.
$1.8B
Commercial Solutions revenues for Q3 2026
6.9%
increase in Commercial Solutions revenues over the same period in 2025
Research & Development Solutions backlog drops to $32.6 billion after $2.1 billion reassessment
Contracted backlog in Research & Development Solutions declined from $34.0 billion at December 31, 2025 to $32.6 billion as of September 30, 2026.
$2.1B
reduction in backlog due to refined assessment criteria on inactive trials
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 4 signals
IQVIA reorganized business operations into two reportable segments effective January 1, 2026
IQVIA updated its operating model and segment reporting from three segments to two: Commercial Solutions and Research & Development Solutions.
IQVIA incurred $63 million in Q2 2026 restructuring costs to streamline global operations
Restructuring costs reached $63 million for Q2 2026 and $114 million for the first six months of 2026, aimed at consolidating functional activities and eliminating redundant positions through 2027.
IQVIA Deploys Solutions Powered by IQVIA Connected Intelligence and Healthcare-grade AI
IQVIA highlighted that its portfolio of solutions is powered by IQVIA Connected Intelligence to provide healthcare intelligence and advanced analytics.
IQVIA Connected IntelligenceHealthcare-grade AIartificial intelligence
Research & Development Solutions backlog expanded to $34.2 billion as of June 30, 2026
Contracted backlog increased from $34.0 billion at December 31, 2025 to $34.2 billion as of June 30, 2026, with approximately $9.2 billion expected to convert to revenue within twelve months.
$34.2B
contracted backlog as of June 30, 2026
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 5 signals
IQVIA consolidated reportable segments from three to two effective January 1, 2026
IQVIA reorganized into two reportable segments - Commercial Solutions and Research & Development Solutions - incorporating Contract Sales & Medical Solutions into Commercial Solutions and moving certain Real-World offerings to R&D Solutions.
IQVIA entered into $650 million Term Loan due 2027 to repay senior notes
On March 11, 2026, IQVIA entered into a 364-Day Term A Loan Agreement to borrow $650 million in U.S.
$650M
Term A loan borrowed to repay €550 million senior notes
Showing 10 of 13 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
IQVIA earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Tech IQ showcased AI partnerships with NVIDIA, Microsoft, AWS, Snowflake, VeevaIQVIA partnered with major enterprise hyperscalers and data platforms to advance clinical and commercial agentic AI offerings. The event gathered over 400 attendees to present joint capabilities. For GTM teams, these existing foundational partnerships highlight ecosystems through which IQVIA co-develops life sciences solutions. | |
| Top 5 pharma selected agentic AI platform for real-world healthcare dataIQVIA secured a major contract with a top 5 pharmaceutical customer to build and operate an agentic platform delivering insights from real-world healthcare data. This win allows the client to accelerate market access decisions and adjust commercial go-to-market models in real time. Vendors offering complementary data management and clinical workflow tools can evaluate integration opportunities. | |
| Large pharma strategic supplier reviews segmented CRO market away from smaller vendorsOver the past 18 months, large pharmaceutical companies conducted extensive reprocurement cycles to renew their strategic partnerships, creating a tri-tier CRO competitive environment. IQVIA reported emerging ahead in partnership scope and win rates against rivals, noting that mid-tier and smaller niche CROs are being displaced from tier-one pharma panels. This dynamic creates prime... | |
| Internal AI agents and process productivity drove 80 bps operational margin gainsIQVIA offset 60 to 70 basis points of pass-through and currency headwinds by generating 80 basis points of operational improvement via AI agent deployment and automation across internal workflows. Automated tasks include offshore software development, software testing, HR, and finance functions. This focus signals internal optimization programs and software modernization across enterprise... | |
| IRA price negotiations and MFN policy extended large pharma procurement cyclesRegulatory headwinds including the Inflation Reduction Act drug pricing negotiations, proposed MFN drug pricing, and tariffs generated significant industry uncertainty that previously extended large pharma decision timelines. While customer RFP flow is now recovering, these regulatory burdens forced clients to pause discretionary spend and capital investments. Sellers to CROs and biopharmas... | |
| Foundational AI models from Anthropic and OpenAI utilized in agent architecturesIQVIA confirmed that it spends money with major foundational model providers including Anthropic and OpenAI to access core tools for building proprietary healthcare agents. Management noted generic tools are embedded within compliant workflows combining IQVIA's proprietary life sciences data and human-in-the-loop oversight. This highlights IQVIA's role as a major buyer of frontier AI model... |
Signal API · MCP
Track IQVIA with the Signal API
One POST /v1/companies/enrich call with iqvia.com returns IQVIA 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"iqvia.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
Related companies
Questions about IQVIA 10-Q
When did IQVIA file its latest 10-Q?
What did IQVIA disclose in its latest 10-Q?
What did IQVIA say on its recent earnings calls?
Where can I read IQVIA's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .